AstraZeneca amends collaboration with Ironwood for Linzess in China
- Details
- Category: AstraZeneca
AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclotide), a first-in-class new treatment for patients with irritable bowel syndrome with constipation (IBS-C).
Educational campaign helps teens and their caregivers tackle the everyday challenges of living with moderate-to-severe atopic dermatitis
- Details
- Category: Sanofi
Teenagers face many challenges, and growing up with a chronic skin disease called atopic dermatitis (AD) can impact the ups and downs and transitions to young adulthood. Sanofi and Regeneron, in partnership with the National Eczema Association (NEA), today launched the next phase of Understand AD, a disease awareness initiative focused on educating people about moderate-to-severe AD.
FDA grants Fast Track designation for Farxiga in heart failure
- Details
- Category: AstraZeneca
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death, or the worsening of heart failure, in adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).
Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that patients who were treated with OCREVUS® (ocrelizumab) continuously for six years or more had reduced risk of disability progression in relapsing MS (RMS) and primary progressive MS (PPMS).
Abbott announces new data that shows artificial intelligence technology can help doctors better determine which patients are having a heart attack
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced that new research, published in the journal Circulation, found its algorithm could help doctors in hospital emergency rooms more accurately determine if someone is having a heart attack or not, so that they can receive faster treatments or be safely discharged.
Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data from OCREVUS® (ocrelizumab) trials in relapsing and primary progressive multiple sclerosis (MS). The analyses provide new insights into the biology of MS that advance the understanding of disease progression, with the goal of identifying and slowing disease progression as early as possible to preserve patient function over the long term.
Boehringer Ingelheim eExpands KRAS cancer program with Lupin's clinical stage MEK inhibitor compound
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin’s lead MEK inhibitor compound in combination with one of Boehringer Ingelheim’s innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.
More Pharma News ...
- Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
- Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer
- Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
- Anniversary of the pivotal RE-LY® trial marks a decade of innovation for stroke prevention in AF patients
- Pfizer invests half billion dollars to advance state-of-the-art gene therapy facility in Sanford, North Carolina
- FDA grants Fast Track designation for Farxiga in chronic kidney disease
- Amgen to acquire Otezla® for $13.4 billion in cash